Favipiravir treatment of mild and moderate new crown patients small stage 3 clinical reach edile.

Recently, the antiviral drug FabiFlu, developed by The Indian pharmaceutical company Glenmark, showed accelerated recovery cycles in patients with mild to moderate symptoms of COVID-19 in a Phase 3 clinical studyThe open-label, randomized, multi-center phase 3 trial, which enrolled 150 patients at seven sites in India, is known to assess the impact of favipiravir combined standard supportive care and placebo supportive care on patients with mild and moderate COVID-19The drug was treated randomly within 48 hours of the patient testing for COVID-19,RT-PCR positive, with participants in the favipiravir group receiving a therapeutic dose of 3600 mg on the first day, followed by a daily dose of 1600 mg for 14 days while receiving standard supportive careThe latest results, released by Glenmark, show that favipiravir increased the virus clearance rate by 28.6 percent to the primary end point compared to placebosIn addition to the faster removal of the virus, favipiravir has reached a number of key secondary endpoints, such as a 40% faster rate of clinical cure, i.ea doctor's assessment of the normalization of clinical symptoms such as patient body temperature, oxygen saturation, respiratory rate and cough;In addition, Glenmark said, 69.8 percent of patients in the favipiravir treatment group reached clinical cure on the fourth day, which was statistically significant compared to 44.9 percent in the control groupIn patients whose clinical condition worsened and needed oxygen support, patients treated with favipiravir took oxygen for an average of 5 days for the first time, and the placebo group for 2 daysFavipiravir was well tolerated in the study and did not have any serious adverse events (SAEs) or deaths; In the favipiravir group of patients 26 cases (35.6%) had adverse events (AEs) and only 6 cases (8%) in the control group, but most AEs were reported to be mild to moderate, with no discontinuation or dose adjustmentA previous small study of 80 patients found that favipiravir reduced virus clearance time compared to lopinavir/ritonavir; 91% improved CT scan results; and the drug had few side effects, but the limitation of the study was that there were no randomized double-blind and placebo-controlledThe latest Phase 3 study made up for the lack of placebo-controlled dataFavipiravir is a broad-spectrum antiviral drug that is a derivative of metalymide, both oral and intravenous, selectively inhibits RNA-dependent RNA polymerase and SARS-CoV-2 virus replication stagesOther studies have shown that the drug induces deadly RNA-transitionmutations that produce unstable viral epithetsFavipiravir was developed and manufactured by the Fujifilm Group and approved in Japan in 2014 for new influenzas (strains that cause more serious diseases) rather than seasonal influenzaHowever, favipiravir has not been shown to be effective in major human airway cells, raising doubts about its efficacy in influenza treatmentLast month, Glenmark received approval from India's drug regulator for the production and sale of FabiFlu, the country's first approved oral drug for the treatment of light and moderate Covid-19Related reading: India approves fapiravin for mild to moderate new coronary pneumonia patients Now Glenmark is conducting another Phase 3 clinical trial in India to assess the efficacy of favipiravir in combination with umifenovir in patients with moderate, hospitalized COVID-19 patientsSource: 1, Glenmark Pharmaceuticals Antiviral Drug Hits the Mark in Small, III COVID-19 Study 2, Coronavirus: Glenmark's Favipiravir positive show results in Phase-3 clinical trials.